No Data
Special treat Beiling (002424.SZ): The new process route for the Tifengtai project has successfully concluded small-scale testing and is currently undergoing pilot verification.
On December 3, Gaolonghui reported that ST Bairui (002424.SZ) stated on the investor interaction platform that the small-scale trial of the new process route for the Tifentai project has been successfully completed, and is currently in the process of verification. If successful, production of samples can be carried out according to the new process, to conduct clinical trials on drug interactions.
Bailing Pharma Gets Clinical Trial Approval for Diabetic Retinopathy Traditional Chinese Tablets; Shares Rise 5%
ST sparrows (002424.SZ): The clinical trial application of its wholly-owned subsidiary Tangning Tongluo tablets has been approved.
Gelonghui, November 12th - Special Treat Bai Ling (002424.SZ) announced that on November 12, 2024, its wholly-owned subsidiary Bai Ling Yuxiu (Zhuhai) Pharmaceutical Co., Ltd. (hereinafter referred to as "Bai Ling Yuxiu") received the "Drug Clinical Trial Approval Notice" (Notice No.: 2024LP02560) issued by the National Medical Products Administration (NMPA). The clinical trial application for Tangning Tong Luo Tablet submitted by Bai Ling Yuxiu has been approved, allowing the product to conduct Phase III clinical trials for diabetic retinopathy.
ST Baoling (002424.SZ): There are currently no drugs directly treating dengue fever.
Gelonghui November 11th | ST Baoling (002424.SZ) stated on the investor interaction platform that the company currently does not have a specific treatment for dengue fever, but suggests that you consult specialized medical institutions or health departments to obtain the latest information and advice on the treatment and prevention of dengue fever.
November 11th A-share investment lightning rod︱ shanghai prosolar resources development: actual controller Yu Zengyun is under investigation for suspected fundraising fraud.
Huibai new materials shareholders the cigna group new materials industry investment fund and its concerted actors intend to collectively reduce their shareholding by no more than 3%; Jiangsu lihua animal husbandry shareholders Tianming agriculture and Cangshi investment intend to collectively reduce their shareholding by no more than 3%; Special treat Bailin is under investigation by the CSRC for suspected violations of information disclosure laws and regulations; Shanghai prosolar resources development's actual controller Yu Zengyun is under investigation for suspected fundraising fraud.
Express News | Special treat Bailing: Received a notice of filing from the China Securities Regulatory Commission for alleged violations of disclosure laws and regulations.
No Data
